|
- Newsroom | CARsgen
This single-arm, single-center, open-label exploratory clinical trial aimed to evaluate the safety and preliminary efficacy of CT071 in patients with high-risk (HR) newly diagnosed multiple myeloma (NDMM) As of January 2, 2025, 10 patients had received CT071 infusion Of these, 6 (60%) patients had high-risk cytogenetics, 3 (30%) had EMD, and 7 (70%) were at R2-ISS III or IV Bridging therapy
- Newsroom | CARsgen
Home - Newsroom - Newsroom CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting Jun 02, 2025
- Newsroom | CARsgen
SHANGHAI, China, June 26, 2025, CARsgen Therapeutics Holdings Limited (Stock Code: 2171 HK), a company focused on developing innovative CAR T-cell therapies, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein
- Newsroom | CARsgen
SHANGHAI, China, June 25, 2025, CARsgen Therapeutics Holdings Limited (Stock Code: 2171 HK), a company focused on developing innovative CAR T-cell therapies, announces that the New Drug Application (NDA) for satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18 2) has been submitted to the Center for Drug Evaluation (CDE) of
- Newsroom | CARsgen
Home - Newsroom - Newsroom CARsgen Announces Positive Topline Results from China GC GEJ Pivotal Phase II Clinical Trial of Claudin18 2 CAR-T (Satri-cel) Dec 30, 2024
- News - CARsgen
Home - Newsroom - Newsroom NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma Mar 01, 2024
- Newsroom | CARsgen
Home - Newsroom - Newsroom CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial Jan 20, 2025
- Newsroom | CARsgen
Home - Newsroom - Newsroom CARsgen’s First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 Feb 10, 2025
|
|
|